Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 32 Fruit Street, Yawkey 5984, Boston, MA 02114, USA.
J Cardiovasc Transl Res. 2013 Aug;6(4):493-500. doi: 10.1007/s12265-013-9459-y. Epub 2013 Apr 5.
ST2 is a member of the interleukin (IL)-1 receptor family discovered in a classical translational science fashion, and exists in two forms, a trans-membrane receptor (ST2L) as well as a soluble decoy receptor (sST2). The ligand of ST2 is IL-33, which is involved in reducing fibrosis and hypertrophy in mechanically strained tissues. In in vitro and in vivo models, ST2L transduces the effects of IL-33, while excess sST2 or abnormalities in ST2 signaling leads to cardiac hypertrophy, fibrosis, and ventricular dysfunction. Clinically, in patients with symptomatic heart failure (HF), elevated concentrations of sST2 are strongly associated with severity of the diagnosis, and powerfully predict increased risk of complications, independent of other established or emerging biomarkers. sST2 testing has also been shown to predict onset of symptomatic HF in patients with acute myocardial infarction, while in community-based subjects, sST2 values independently predict future HF, cardiovascular disease events, and mortality.
ST2 是白介素 (IL)-1 受体家族的成员，是通过经典的转化科学方法发现的，有两种形式，一种是跨膜受体 (ST2L)，另一种是可溶性诱饵受体 (sST2)。ST2 的配体是 IL-33，它参与减少机械应变组织中的纤维化和肥大。在体外和体内模型中，ST2L 转导 IL-33 的作用，而过量的 sST2 或 ST2 信号异常导致心肌肥大、纤维化和心室功能障碍。临床上，在有症状心力衰竭 (HF) 的患者中，sST2 的浓度升高与诊断的严重程度密切相关，并有力地预测并发症风险增加，独立于其他已建立或新兴的生物标志物。sST2 检测也已被证明可预测急性心肌梗死后有症状 HF 的发病，而在社区为基础的研究对象中，sST2 值独立预测未来 HF、心血管疾病事件和死亡率。
